Find policies, billing codes, payers, states, and providers
CPT 0488U: Unity Fetal Antigen NIPT for Alloimmunization
CPT code 0488U designates a Proprietary Laboratory Analysis (PLA) for the Unity Fetal Antigen™ NIPT from BillionToOne Laboratory. This cell–free DNA sequencing test detects specific fetal antigens (Rh, C, c, D, E, Duffy (Fya), and Kell (K)) in pregnancies complicated by maternal alloimmunization to identify fetuses at risk for Hemolytic Disease of the Fetus and Newborn (HDFN). As a PLA code tied to a single manufacturer and assay, CPT code 0488U clarifies coding for payers and providers when reporting this proprietary prenatal screening.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national overview of clinical context, coding considerations, and typical sites of service for this lab-based prenatal screening. Readers will find concise benchmarks and policy context relevant to coverage and billing of proprietary noninvasive prenatal tests, an explanation of the clinical utility in alloimmunized pregnancies, and what payers commonly evaluate when considering coverage for PLA-designated assays. Data not available in the input are identified explicitly where applicable.
Customize your policy alerts
Sign up for cpt 0488U policy alerts
Get alerted when payer policies referencing 0488U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0488U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Unity Fetal Antigen™ NIPT offered by BillionToOne Laboratory, BillionToOne Inc. The test uses cell–free DNA sequencing from maternal blood to detect the presence or absence of specific fetal antigens — including Rh, C, c, D, E, Duffy (Fya), and Kell (K) — for pregnancies in which the pregnant person has alloimmunization. The result helps identify pregnancies at increased risk for Hemolytic Disease of the Fetus and Newborn (HDFN) and guides which pregnancies will most benefit from additional fetal monitoring.
Service type: Proprietary noninvasive prenatal screening using cell–free DNA sequencing
Typical site of service: Clinical laboratory processing with blood draw performed in outpatient phlebotomy settings, obstetrics clinics, or hospital outpatient departments